Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

30.05
-1.8100-5.68%
Post-market: 32.902.85+9.48%18:43 EDT
Volume:1.76M
Turnover:52.96M
Market Cap:1.55B
PE:77.05
High:32.37
Open:31.73
Low:29.43
Close:31.86
52wk High:90.32
52wk Low:29.43
Shares:51.62M
Float Shares:44.87M
Volume Ratio:1.11
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:6.01%
ROA:2.09%
PB:3.45
PE(LYR):77.05

Loading ...

Stock Track | Soleno Therapeutics Plunges 8.32% in Pre-Market After TD Cowen Slashes Price Target

Stock Track
·
Feb 26

Soleno Therapeutics Names Jennifer Fulk CFO as James Mackaness Retires

Reuters
·
Feb 26

Soleno Therapeutics Inc - on Feb 25, Co Appoints Jennifer Fulk as CFO Effective March 2, 2026 - SEC Filing

THOMSON REUTERS
·
Feb 26

U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite

Reuters
·
Feb 26

Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating

TIPRANKS
·
Feb 26

Soleno Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year

TIPRANKS
·
Feb 26

Soleno Therapeutics Q4 EPS $0.80 Beats $0.69 Estimate, Sales $91.730M Beat $88.548M Estimate

Benzinga
·
Feb 26

Stock Track | Soleno Therapeutics Soars 6.26% Intraday on Strong Q4 Earnings

Stock Track
·
Feb 26

BRIEF-Soleno Therapeutics Q4 EPS USD 0.8

Reuters
·
Feb 26

Soleno posts SLNO FY 2025 net income of USD 20.9 million as VYKAT XR FY product revenue hits USD 190.4 million

Reuters
·
Feb 26

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

GlobeNewswire
·
Feb 26

Earning Preview: Soleno Therapeutics this quarter’s revenue is expected to increase by 34.12%, and institutional views are bullish

Earnings Agent
·
Feb 18

Soleno Therapeutics Inc. published an update to their financial calendar

Reuters
·
Feb 11

A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates

Simply Wall St.
·
Feb 03

Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating

TIPRANKS
·
Jan 29

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

TIPRANKS
·
Jan 29

Soleno Therapeutics to Participate in Upcoming Conferences

GlobeNewswire
·
Jan 29

Soleno Therapeutics Boosts Executive Pay and Severance Benefits

Reuters
·
Jan 26

Soleno Therapeutics Updates Executive Compensation and Severance Plans

TIPRANKS
·
Jan 24